{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:34:45Z","timestamp":1783488885563,"version":"3.55.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T00:00:00Z","timestamp":1493424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which unregulated hypersecretion of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMT) causes renal phosphate wasting, hypophosphatemia, and osteomalacia. The resulting mineral homeostasis abnormalities and skeletal manifestations can be reversed with surgical resection of the tumor. Unfortunately, PMTs are often difficult to locate, and medical treatment with oral phosphate and vitamin D analogues is either insufficient to manage the disease or not tolerated. Octreotide has been proposed as a potential treatment for TIO due to the presence of somatostatin receptors (SSTR) on PMTs; however, the role of somatostatin signaling in PMTs and the efficacy of treatment of TIOs with somatostatin analogues is not clear. In an effort to evaluate the efficacy of octreotide therapy in TIO, five subjects with TIO were treated with octreotide for 3 days. Blood intact FGF23, phosphate, and 1,25(OH)2D3, and tubular reabsorption of phosphate (TRP) were measured at frequent time points during treatment. Octreotide's effects were assessed by comparing group means of the biochemical parameters at each time-point to mean baseline values. There were no significant changes in blood phosphate, FGF23, 1,25(OH)2D3, or TRP during octreotide treatment, consistent with a lack of efficacy of octreotide in treating TIO. \u00a9 2017 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.3162","type":"journal-article","created":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T15:09:07Z","timestamp":1493651347000},"page":"1667-1671","source":"Crossref","is-referenced-by-count":16,"title":["Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy"],"prefix":"10.1093","volume":"32","author":[{"given":"Diana","family":"Ovejero","sequence":"first","affiliation":[{"name":"Skeletal Clinical Studies UnitCraniofacial and Skeletal Disease BranchNational Institute of Dental and Craniofacial Research (NIDCR)National Institutes of Health (NIH)BethesdaMDUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala","family":"El-Maouche","sequence":"additional","affiliation":[{"name":"Clinical CenterNational Institutes of Health (NIH)BethesdaMDUSA"},{"name":"Skeletal Clinical Studies UnitCraniofacial and Skeletal Disease BranchNational Institute of Dental and Craniofacial Research (NIDCR)National Institutes of Health (NIH)BethesdaMDUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A","family":"Brillante","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies UnitCraniofacial and Skeletal Disease BranchNational Institute of Dental and Craniofacial Research (NIDCR)National Institutes of Health (NIH)BethesdaMDUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azar","family":"Khosravi","sequence":"additional","affiliation":[{"name":"Department of EndocrinologyDiabetes and Metabolism City of Hope National Medical CenterDuarteCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel I","family":"Gafni","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies UnitCraniofacial and Skeletal Disease BranchNational Institute of Dental and Craniofacial Research (NIDCR)National Institutes of Health (NIH)BethesdaMDUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Collins","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies UnitCraniofacial and Skeletal Disease BranchNational Institute of Dental and Craniofacial Research (NIDCR)National Institutes of Health (NIH)BethesdaMDUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,29]]},"reference":[{"issue":"3","key":"2024021014201203600_jbmr3162-bib-0001","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","article-title":"Tumor-induced osteomalacia","volume":"18","author":"Chong","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2024021014201203600_jbmr3162-bib-0002","first-page":"1922","article-title":"Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification","volume":"56","author":"Reubi","year":"1996","journal-title":"Cancer Res"},{"issue":"4","key":"2024021014201203600_jbmr3162-bib-0003","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2265.2001.01056.x","article-title":"Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy","volume":"54","author":"Rhee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"26","key":"2024021014201203600_jbmr3162-bib-0004","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","article-title":"Octreotide therapy for tumor-induced osteomalacia","volume":"345","author":"Seufert","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"2024021014201203600_jbmr3162-bib-0005","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","article-title":"68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia","volume":"101","author":"El-Maouche","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"2024021014201203600_jbmr3162-bib-0006","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2169\/internalmedicine.45.1797","article-title":"Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy","volume":"45","author":"Yoshioka","year":"2006","journal-title":"Intern Med"},{"issue":"3","key":"2024021014201203600_jbmr3162-bib-0007","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/EJE-07-0779","article-title":"Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling","volume":"158","author":"van Boekel","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"22","key":"2024021014201203600_jbmr3162-bib-0008","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJM200205303462215","article-title":"Octreotide for tumor-induced osteomalacia","volume":"346","author":"Paglia","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"2024021014201203600_jbmr3162-bib-0009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.lpm.2010.10.011","article-title":"Curative surgical treatment after inefficient long-acting somatostatin analogues therapy of a tumor-induced osteomalacia","volume":"40","author":"Mekinian","year":"2011","journal-title":"Presse Med"},{"issue":"12","key":"2024021014201203600_jbmr3162-bib-0010","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.humpath.2013.07.016","article-title":"Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A)","volume":"44","author":"Houang","year":"2013","journal-title":"Hum Pathol"},{"issue":"11","key":"2024021014201203600_jbmr3162-bib-0011","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/RLU.0b013e31818866bf","article-title":"Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia","volume":"33","author":"Duet","year":"2008","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2024021014201203600_jbmr3162-bib-0012","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"2024021014201203600_jbmr3162-bib-0013","author":"Carpenter"},{"issue":"6","key":"2024021014201203600_jbmr3162-bib-0014","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1359\/jbmr.070304","article-title":"Cinacalcet in the management of tumor-induced osteomalacia","volume":"22","author":"Geller","journal-title":"J Bone Miner Res. 2007"},{"issue":"3","key":"2024021014201203600_jbmr3162-bib-0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2024021014201203600_jbmr3162-bib-0016","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/modpathol.2016.137","article-title":"Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors","volume":"29","author":"Lee","year":"2016","journal-title":"Mod Pathol"},{"issue":"4","key":"2024021014201203600_jbmr3162-bib-0017","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jbmr.1810","article-title":"Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets","volume":"28","author":"Wohrle","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2024021014201203600_jbmr3162-bib-0018","article-title":"Striking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398","author":"Collins","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014201203600_jbmr3162-bib-0019","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2165\/00003495-198938050-00002","article-title":"Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion","volume":"38","author":"Battershill","year":"1989","journal-title":"Drugs"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/32\/8\/1667\/56653090\/jbmr3162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/32\/8\/1667\/56653090\/jbmr3162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:59:03Z","timestamp":1710341943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/32\/8\/1667-1671\/7605676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,29]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,4,29]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3162","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8,1]]},"published":{"date-parts":[[2017,4,29]]}}}